Search

Your search keyword '"Mansi, L."' showing total 332 results
Start Over Author "Mansi, L." Publication Type Academic Journals

Refine your results

more »

more »

more »

more »
332 results on '"Mansi, L."'

2. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., and O’Shaughnessy, J.

Published
2021
Full Text
View/download PDF

8. 660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study

Author

Mansi, L., Ghiringhelli, F., de la Fouchardiere, C., You, B., Kalbacher, E., Bazan, F., Fagnoni Legat, C., Meynard, G., Maurina, T., Vienot, A., Vernerey, D., Meurisse, A., Fumet, J-D., Kroemer, M., Tanang, A., Rebucci-Peixoto, M., Spehner, L., Kim, S., Adotevi, O., and Borg, C.

Published
2024
Full Text
View/download PDF

9. The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

Author

Orillard, E., Spehner, L., Mansi, L., Bouard, A., Falcoz, A., Lepiller, Q., Renaude, E., Pallandre, J. R., Vienot, A., Kroemer, M., and Borg, C.

Subjects
T cells, CANCER patients, COVID-19, COVID-19 pandemic, VACCINE effectiveness
Abstract

Purpose: Cancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. Nevertheless, we observe a failure of COVID-19 vaccines in this vulnerable population. We hypothesize that senescent peripheral T-cells alter COVID-19 vaccine-induced immunity. Methods: We performed a monocentric prospective study and enrolled cancer patients and healthy donors before the COVID-19 vaccination. The primary objective was to assess the association of peripheral senescent T-cells (CD28-CD57+KLRG1+) with COVID-19 vaccine-induced immunity. Results: Eighty cancer patients have been included, with serological and specific T-cell responses evaluated before and at 3 months post-vaccination. Age ≥ 70 years was the principal clinical factor negatively influencing the serological (p=0.035) and specific SARS-CoV-2 T-cell responses (p=0.047). The presence of senescent T-cells was correlated to lower serological (p=0.049) and specific T-cell responses (p=0.009). Our results sustained the definition of a specific cutoff for senescence immune phenotype (SIP) (≥ 5% of CD4 and ≥ 39.5% of CD8 T-cells), which was correlated to a lower serological response induced by COVID-19 vaccination for CD4 and CD8 SIPhigh (p=0.039 and p=0.049 respectively). While CD4 SIP level had no impact on COVID-19 vaccine efficacy in elderly patients, our results unraveled a possible predictive role for CD4 SIPhigh T-cell levels in younger cancer patients. Conclusions: Elderly cancer patients have a poor serological response to vaccination; specific strategies are needed in this population. Also, the presence of a CD4 SIPhigh affects the serological response in younger patients and seems to be a potential biomarker of no vaccinal response. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?

Author

Thibault, G., Kfoury, M., Lorusso, D., Floquet, A., Ventriglia, J., Salaun, H., Moubarak, M., Rivoirard, R., Polastro, L., Favier, L., You, B., Berton-Rigaud, D., De La Motte Rouge, T., Mansi, L., Abdeddaim, C., Prulhiere, K., Lancry Lecomte, L., Provansal Gross, M., Dalban, C., and Ray-Coquard, I.L.

Published
2022
Full Text
View/download PDF

19. Novel applications of myocardial perfusion imaging oral abstract session

Author

Lautamäki, R. Riikka, Airaksinen, K. E. J., Seppänen, M., Toikka, J., Luotolahti, M., Borra, R., Sundell, J., Knuuti, J., Nuutila, P., Hermann, S. Sven, Levkau, B., Theilmeier, G., Giet, M. Van der, Chun, J., Schober, O., Schäfers, M., Spadafora, M. Marco, Manganelli, F., Ferro, A., Varrella, P., Rizzo, V., Mansi, L., Rosato, G., Miletto, P., Cuocolo, A., Tsukamoto, T. Takahiro, Morita, K., Naya, M., Katoh, C., Kuge, Y., Okamoto, H., Tsutsui, H., Tamaki, N., Morita, K. Koichi, Tsukamoto, T., Naya, M., Noriyasu, K., Mabichi, M., Kageyama, H., Tamaki, N., Varani, K., Shryock, J. C., Belardinelli, L. Luiz, and Borea, P. A.

Published
2005
Full Text
View/download PDF

24. 1789P - Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients

Author

Mouillet, G., Fritzsch, J., Thiery-Vuillemin, A., Meneveau, N., Almotlak, H., Mansi, L., Curtit, E., Kim, S., Jary, M., Maurina, T., Eberst, G., Barthelemy, P., Eymard, J.-C., Geoffrois, L., Djoumakh, O., Anota, A., Adotevi, O., Westeel, V., and Paget-Bailly, S.

Published
2019
Full Text
View/download PDF

28. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay.

Author

Curtit, E., Mansi, L., Maisonnette-Escot, Y., Sautière, J.-L., and Pivot, X.

Subjects
BREAST cancer prognosis, BREAST cancer patients, CANCER relapse, BREAST cancer chemotherapy, CANCER hormone therapy
Abstract

Although useful prognostic and predictive insights can be gained from patient and tumour characteristics in early-stage breast cancer, it is not always straightforward to predict the likely risk of recurrence for each individual patient following breast surgery. One of the most difficult challenges faced by clinicians is identifying patients who may benefit most from adjuvant chemotherapy, and distinguishing these cases from those where endocrine therapy may be sufficient for cure. Genomic tests such as the Oncotype DX ® Breast Recurrence Score ® Assay have been developed to provide a robust and clinically validated assessment of a patient's individual tumour signature. The Oncotype DX Assay is included in treatment guidelines for estimating both the risk of distant recurrence and predicting adjuvant chemotherapy benefit for early-stage breast cancer patients with human epidermal growth factor receptor 2-negative, oestrogen-receptor positive, and axillary lymph node negative or positive (1–3 positive nodes) disease. In this article, we review unmet needs for prognostication and prediction in early-stage breast cancer, and consider how the information provided by the Recurrence Score is complementary to that gained from the assessment of more traditional clinicopathologic criteria. Routine use of the assay in clinical practice, limitations and possible future directions are also discussed. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

34. Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: Lack of lymphocyte recovery as a major contributing factor.

Author

Mansi, L., Daguindau, E., Saas, P., Pouthier, F., Ferrand, C., Dormoy, A., Patry, I., Garnache, F., Rohrlich, P.-S., Deconinck, E., and Larosa, F.

Subjects
*NOCARDIOSIS, *BONE marrow cells, *LYMPHOCYTES, *BACTERIAL diseases, *AIDS patients, *DIAGNOSIS, *THERAPEUTICS, *TRANSPLANTATION of organs, tissues, etc.
Abstract

Abstract: Hematopoietic cell transplantation (HCT) is a curative treatment for hematological malignancies. This therapeutic approach is associated with a profound immune deficiency and an increased rate of opportunistic infections. Nocardiosis is a rare bacterial infection occurring mainly in patients with deficient cell-mediated immunity, such as AIDS patients or transplant recipients. Diagnosis of nocardiosis can be challenging, as signs and symptoms are non-specific. Routine prophylaxis with trimethoprin/sulfamethoxazole (TMP/SMZ) does not prevent the risk of infection. Between May 2001 and December 2009, five cases of nocardiosis were diagnosed from the 366 allogeneic HCT recipients in our centre. Four patients developed a disseminated nocardiosis within the first year after HCT. The fifth patient presented a localized cutaneous nocardiosis. In disseminated cases, median total CD4+ T-cells were below 100cells/μL. Naive CD4+ CD45RA+/RO− T-cells were almost undetectable. CD8+ T-cells and NK cells were below the normal range and CD19+ B-cell reconstitution was completely deficient. In a localized case, we observed a lack of naive thymic emigrants CD4+ CD45RA+/RO− T-cells. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

35. THE ROLE OF POSITRON EMISSION TOMOGRAPHY IN INFLAMMATORY BOWEL DISEASE.

Author

CISTARO, A., QUARTUCCIO, N., MANSI, L., SIGNORE, A., DOLCI, M., and TREGLIA, G.

Subjects
POSITRON emission tomography, INFLAMMATORY bowel diseases, INFLAMMATION, CROHN'S disease, ULCERATIVE colitis, GASTROINTESTINAL system, RADIOLOGY, ENDOSCOPY, COMPUTED tomography, EQUIPMENT & supplies
Abstract

Inflammatory bowel diseases (IBD) are a group of pathological conditions characterized by chronic inflammation of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. To date, imaging of IBD is based on several radiological techniques such as barium studies, magnetic resonance imaging, and computed tomography (CT). Endoscopy is the gold standard for the assessment of the large bowel and proximal small intestine in patients with IBD allowing the biopsy of the visualized bowel. Positron emission tomography (PET) and PET/CT with Fluorine-18-fluoro-2-deoxy-D-glucose (FDG) is a functional imaging method used to detect abnormalities in glucose metabolism in a variety of disorders. FDG accumulates mainly in tumours, but increased uptake and retention has been shown also in lesions with a high concentration of inflammatory cells, such as granulocytes and activated macrophages. Recent literature data demonstrate that FDG-PET and PET/CT may be useful noninvasive tools for identifying and localizing active IBD. In patients with an established diagnosis of IBD, FDG-PET and PET/CT may provide information about disease activity, location and extent of the disease within the intestinal tract, allowing early recognition of disease relapse and possible complications. Furthermore, these techniques may play a role in assessing the treatment response to medical therapy in patients with IBD. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

36. Perspectives of nuclear diagnostic imaging in diabetic cardiomyopathy.

Author

Sasso, F.C., Rambaldi, P.F., Carbonara, O., Nasti, R., Torella, M., Rotondo, A., Torella, R., and Mansi, L.

Abstract

Abstract: Diabetic cardiomyopathy is a ventricular dysfunction in the absence of coronary artery disease, valvular or hypertensive heart disease. The mechanisms underlying diabetic cardiomyopathy may involve metabolic disturbances, myocardial fibrosis, small vessel disease, microcirculation abnormalities, cardiac autonomic neuropathy and insulin resistance. Diagnostic problems emerge because no specific disease pattern characterizes the disease and because there may be coexistence in diabetes of coronary artery disease and hypertension as independent but compounding causes of biochemical, anatomical and functional alterations impairing cardiac function. In this paper we will review the role of nuclear imaging today, concentrating on the diagnostic capabilities of radionuclide ventriculography, to study the effect of insulin resistance and, more extensively, gated-single photon emission computed tomography with Tc-99m labelled agents. A broad analysis will be dedicated to: 1) positron emission tomography using perfusion agents, with the potential to quantify resting and stress blood flow and coronary flow reserve; 2) radionuclide procedures evaluating aerobic and anaerobic cardiac metabolism; and 3) cardiac neurotransmission imaging, studying the autonomic neuropathy. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

40. An unusual case of primary systemic amyloidosis.

Author

Ambrosone, L., Mansi, L., Salvatore, T., Marino, F., Orabona, P., Rambaldi, A., Rambaldi, P. F., and Rambaldi, M.

Subjects
*AMYLOIDOSIS, *EAR canal, *TECHNETIUM, *PREDNISONE, *COLCHICINE, *THERAPEUTICS
Abstract

Here we report an unusual case of primary systemic amyloidosis. The cutaneous lesions were polymorphic and included involvement of both external auditory canals. The visceral involvement was covert. Mapping of amyloid deposits was performed using scintigraphy with technetium-99m (V) dimercaptosuccinic acid ([[sup99m]Tc (V)]] DMSA). Therapy with melphalan, prednisone and colchicine resulted in considerable improvement. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

41. Positron emission tomography in generalized seizures.

Author

Theodore, William H., Brooks, Rodney, Margolin, Richard, Patronas, Nicholas, Sato, Susumu, Porter, Roger J., Mansi, Luigi, Bairamian, Dikran, DiChiro, Giovanni, Theodore, W H, Brooks, R, Margolin, R, Patronas, N, Sato, S, Porter, R J, Mansi, L, Bairamian, D, and DiChiro, G

Published
1985
Full Text
View/download PDF

43. Quantitative assessment of blood-brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography.

Author

Pozzilli, C, Bernardi, S, Mansi, L, Picozzi, P, Iannotti, F, Alfano, B, Bozzao, L, Lenzi, G L, Salvatore, M, and Conforti, P

Subjects
BLOOD-brain barrier, CAPILLARY permeability, COMPARATIVE studies, ETHYLENEDIAMINETETRAACETIC acid, GALLIUM isotopes, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, MULTIPLE sclerosis, RADIOISOTOPES, RESEARCH, POSITRON emission tomography, EVALUATION research
Abstract

Fifteen patients with definite multiple sclerosis were examined with high volume delayed (HVD) CT scan and positron emission tomography (PET) using 68-Ga-EDTA as a tracer. The passage of 68-Ga-EDTA across the blood-brain barrier (BBB) was measured by using multiple graphical analysis. This method permits the simultaneous calculation of a blood to brain influx constant Ki (ml/g-1 min-1) and of the plasma volume Vp (ml/g-1). Focal areas of abnormal CT enhancement and pathological accumulation of 68-Ga-EDTA were visualised in four patients who were all examined during a clinical exacerbation of the disease. The mean Ki value measured in these areas was 12.5, SD 3.4 indicating a moderate but significant increase of BBB permeability compared with the value found in normal tissue (3.2, SD 0.9). No parallel increase in Vp values was found in these pathological areas. Quantitative data obtained with PET seems to provide further insight into the study of BBB function in multiple sclerosis. [ABSTRACT FROM AUTHOR]

Published
1988

Catalog

Books, media, physical & digital resources
See catalog results